前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与生化复发前列腺癌挽救性放疗患者肿瘤学结局改善相关
该研究纳入610例机器人辅助根治性前列腺切除术后生化复发并接受挽救性放疗的患者,其中298例在放疗前接受PSMA-PET/CT,312例未接受。经病例对照匹配后每组各108例,未接受PSMA-PET/CT组1年生化进展23例(21%),接受组9例(8%)(p=0.007)。结论认为PSMA-PET/CT与挽救性放疗后肿瘤学结局改善相关。
要点
- 匹配后未行PSMA-PET/CT组1年生化进展23/108(21%),行PSMA-PET/CT组9/108(8%)(p=0.007)。
- 匹配变量包括挽救性放疗开始时PSA值、病理分级分组、病理T分期、手术切缘状态及RARP后生化持续。
- 研究未加用激素治疗,结局为挽救性放疗后1年生化进展。
核心结论
- PSMA-PET/CT与机器人辅助根治性前列腺切除术后生化复发接受挽救性放疗患者的肿瘤学结局改善相关。
研究设计与样本
- 研究纳入610例接受挽救性放疗的患者,其中298例在放疗前接受PSMA-PET/CT,312例未接受。
- 采用病例对照匹配,匹配变量为挽救性放疗开始时PSA值、病理分级分组、病理T分期、手术切缘状态及RARP后生化持续。
- 未处方额外激素治疗,结局变量为挽救性放疗后1年生化进展,定义为PSA较放疗后最低值升高≥0.2 ng/ml或开始额外治疗。
主要发现
- 匹配后两组各108例;未接受PSMA-PET/CT组108例中23例(21%)在挽救性放疗后1年出现生化进展,接受PSMA-PET/CT组108例中9例(8%)出现生化进展(p=0.007)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiolabeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has shown superior diagnostic accuracy to conventional imaging for the detection of prostate cancer deposits . Consequently, clinical management changes have been reported in patients with biochemical recurrence (BCR) of disease after robot-assisted radical prostatectomy (RARP). We hypothesized that, due to the exclusion of patients with metastatic disease on PSMA-PET/CT, those who underwent local salvage radiation therapy (SRT) after restaging PSMA-PET/CT for BCR may have better oncological outcomes than patients who underwent "blind" SRT. OBJECTIVE: To compare the oncological outcome of a patient cohort that underwent PSMA-PET imaging prior to SRT with that of a patient cohort that did not have PSMA-PET imaging before SRT. DESIGN, SETTING, AND PARTICIPANTS: We included 610 patients who underwent SRT, of whom 298 underwent PSMA-PET/CT prior to SRT and 312 did not. No additional hormonal therapy was prescribed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: To compare both cohorts, case-control matching was performed, using the prostate-specific antigen (PSA) value at the initiation of SRT, pathological grade group, pathological T stage, surgical margin status, and biochemical persistence after RARP as matching variables. The outcome variable was biochemical progression at 1 yr after SRT, defined as either a rise of PSA ≥0.2 ng/ml above the nadir after SRT or the start of additional treatment. RESULTS AND LIMITATIONS: After case-control matching, 216 patients were matched in both cohorts (108 patients per cohort). In the patient cohort without PSMA-PET/CT prior to SRT, of 108 patients, 23 (21%) had biochemical progression of disease at 1 yr after SRT, compared with nine (8%) who underwent restaging PSMA-PET/CT prior to SRT (p = 0.007). CONCLUSIONS: PSMA-PET/CT is found to be associated with an improved oncological outcome in patients who undergo SRT for BCR after RARP. PATIENT SUMMARY: Performing prostate-specific membrane antigen positron emission tomography/computed tomography imaging in patients with biochemical recurrence of disease after robot-assisted radical prostatectomy, before initiating salvage radiation therapy, resulted in improved short-term oncological outcomes.
引用
- Meijer D, Eppinga WSC, Mohede RM, et al. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. Eur Urol Oncol. 2022. PMID: 35074282. doi:10.1016/j.euo.2022.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。